Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
1.600
-0.150 (-8.57%)
At close: Jun 27, 2025, 4:00 PM
1.680
+0.080 (5.00%)
After-hours: Jun 27, 2025, 5:57 PM EDT
Outlook Therapeutics Employees
Outlook Therapeutics had 23 employees as of September 30, 2024. The number of employees decreased by 1 or -4.17% compared to the previous year.
Employees
23
Change (1Y)
-1
Growth (1Y)
-4.17%
Revenue / Employee
n/a
Profits / Employee
$918,299
Market Cap
68.57M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
OTLK News
- 10 days ago - Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event - GlobeNewsWire
- 18 days ago - Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD - GlobeNewsWire
- 26 days ago - Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD - GlobeNewsWire
- 5 weeks ago - Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering - GlobeNewsWire
- 5 weeks ago - Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants - GlobeNewsWire
- 6 weeks ago - Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD - GlobeNewsWire
- 4 months ago - Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration - GlobeNewsWire